D
Pyxis Oncology, Inc. PYXS
$1.04 -$0.02-1.89% NASDAQ
Recommendation
Prev Close
$1.06
Volume
303,908
Avg Vol (90D)
636,835
Market Cap
$65.29M
Dividend & Yield
--
52-Week Range
$0.8332 - $5.39
P/E (TTM)
--
EPS (TTM)
-$1.28
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
William Blair Sticks to Their Hold Rating for Pyxis Oncology (PYXS)
4/28/2025 - TipRanks Financial Blog
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of ...
4/25/2025 - GuruFocus
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of ...
4/25/2025 - GuruFocus
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
4/25/2025 - Globe Newswire
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
4/24/2025 - Zacks Investment Research
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
4/23/2025 - Zacks Investment Research
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Moderate Buy" by Analysts
4/18/2025 - MarketBeat
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
4/16/2025 - Zacks Investment Research
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
4/2/2025 - GuruFocus
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
4/2/2025 - Globe Newswire
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC ...
3/25/2025 - GuruFocus
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
3/25/2025 - Globe Newswire
Pyxis Oncology Highlights Strategic Focus on Lead Candidate
3/24/2025 - TipRanks Financial Blog
Stifel Nicolaus Keeps Their Buy Rating on Pyxis Oncology (PYXS)
3/24/2025 - TipRanks Financial Blog
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Moderate Buy" by Brokerages
3/23/2025 - MarketBeat
HC Wainwright Forecasts Stronger Earnings for Pyxis Oncology
3/22/2025 - MarketBeat
William Blair Comments on Pyxis Oncology Q1 Earnings
3/22/2025 - MarketBeat
William Blair Comments on Pyxis Oncology FY2027 Earnings
3/21/2025 - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Given Outperform Rating at Royal Bank of Canada
3/20/2025 - MarketBeat
Pyxis Oncology's (PYXS) "Buy" Rating Reiterated at HC Wainwright
3/20/2025 - MarketBeat
RBC Capital Remains a Buy on Pyxis Oncology (PYXS)
3/20/2025 - TipRanks Financial Blog
HC Wainwright Reiterates "Buy" Rating for Pyxis Oncology (NASDAQ:PYXS)
3/19/2025 - Ticker Report
Pyxis Oncology (NASDAQ:PYXS) Releases Earnings Results, Hits Expectations
3/19/2025 - MarketBeat
Pyxis Oncology GAAP EPS of -$1.32 misses by $1.02
3/19/2025 - SeekingAlpha.com: All News
Pyxis Oncology Inc (PYXS) Reports Annual EPS of ($1.32) and Revenue of $16. ...
3/19/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$16.15M
EBITDA (TTM)
-$62.59M
EBIT (TTM)
-$65.57M
Net Income (TTM)
-$77.33M
Balance Sheet
Total Assets (Q)
$157.18M
Total Debt (Q)
$20.20M
Total Liabilities (Q)
$36.43M
Book Value Per Share (Q)
$2.01
Cash Flow
Cash from Operations (TTM)
-$57.67M
Cash from Investing (TTM)
$8.16M
Cash from Financing (TTM)
$59.33M
Net Change in Cash (TTM)
$9.81M
Filings
Filing Date
Tuesday, March 18, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.44
7-Day Total Return
11.36%
30-Day Total Return
-6.31%
60-Day Total Return
-35.80%
90-Day Total Return
-35.80%
Year to Date Total Return
-38.46%
1-Year Total Return
-75.81%
2-Year Total Return
-62.72%
3-Year Total Return
-61.05%
5-Year Total Return
--
52-week Low
Apr 07, 2025 - $0.8332
52-week High
Nov 11, 2024 - $5.39
Valuation
Market Cap
$65.29M - Micro Cap
Enterprise Value
-$41.45M
Price/Sales (TTM)
4.02
Price/Book (Q)
0.53
Dividends and Shares
Shares Outstanding
61.25M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.pyxisoncology.com
Phone Number
617 453 3596
Address
321 Harrison Avenue
Boston, MA 02118
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an... more
NASDAQ 04/28/2025 4:00PM Eastern Quotes delayed